Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
December 17, 2020 02:00 ET | Source: Amryt Pharma plc Amryt Pharma plc
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce Ministry of Health reimbursement approval has been granted for Lojuxta® (lomitapide) in the Kingdom of Saudi Arabia.
Lojuxta® has been approved as an adjunct to a low-fat diet and other lipid-lowering treatments, with or without low density lipoprotein (LDL) apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolaemi
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1 – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Sequana Medical : announces January 2021 Investor Conference Schedule
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Vectura Group plc Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565 Mary-Jane Elliott / Sue Stuart / David Daley
About Vectura Vectura is a provider of innovative inhaled drug delivery solutions that enable partners and customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, Bayer, Chiesi, Almirall, and Tianjin KingYork.
Ovoca Bio is a European-based biopharmaceutical company with a focus on women s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD). The Company s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD. Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.